<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02032290</url>
  </required_header>
  <id_info>
    <org_study_id>Ticagrelor - Clopidogrel</org_study_id>
    <nct_id>NCT02032290</nct_id>
  </id_info>
  <brief_title>Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Policlinico Umberto I</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Policlinico Umberto I</source>
  <brief_summary>
    <textblock>
      The administration of these drugs is realized according to the European Society of Cardiology&#xD;
      guidelines.&#xD;
&#xD;
      All patients will be pretreated with aspirin 300 mg orally, heparin iv to maintain an&#xD;
      activated clotting time of &gt;250 sec, and a loading dose of ticagrelor (180 mg) or clopidogrel&#xD;
      (600 mg) immediately before the revascularization. The list of assignment to ticagrelor or&#xD;
      clopidogrel will be generated by a computer according to a 1:1 randomization. Primary&#xD;
      Percutaneous Coronary Intervention will be performed according to standard clinical practice&#xD;
      using femoral or radial artery Judkins approach via six or seven French heath insertion.&#xD;
      After crossing the target occlusive Lesion, coronary stenting will be performed based on&#xD;
      standard practice. Patients subsequently will receive heparin for 48 hr, aspirin 100 mg&#xD;
      daily, and clopidogrel (75 mg/day) or ticagrelor (90 mg twice daily) for at least 12 months.&#xD;
      Other adjunctive pharmacotherapy in Intensive Care Unit will be administered according to&#xD;
      operator discretion. All patients will provide written informed consent before entering the&#xD;
      study.&#xD;
&#xD;
      Before and after the procedure a 12-leads ECG and an echocardiogram will be performed as&#xD;
      standard practice. Then, all the pre-, intra-, and post-procedure data patients will be&#xD;
      collected in a database.&#xD;
&#xD;
      Investigators aim to perform a prospective, single-center, investigator-initiated, randomized&#xD;
      study to compare the Adenosine-induced coronary vasodilatation after the loading dose of&#xD;
      Ticagrelor either Clopidogrel during the Percutaneous Coronary Intervention. Patients with&#xD;
      Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention will be enrolled in the&#xD;
      study and will be randomized, in a 1:1 ratio, to receive a loading dose of Ticagrelor (180&#xD;
      mg) or Clopidogrel (600 mg). Coronary Flow Reserve will be recorded by intracoronary Doppler&#xD;
      Flow Wire before the stent implantation and after the procedure at baseline and 2-minute&#xD;
      later adenosine intravenous administration at incremental doses of 50, 80, 110 and 140&#xD;
      ug/Kg/min with 2 minutes interval between infusions.&#xD;
&#xD;
      Coronary Flow Reserve is the ability of the myocardium to increase blood flow in response to&#xD;
      maximal exercise. Doppler Flow Wire allows to measure this increase expressing it as a ratio&#xD;
      between maximal vasodilation and flow at rest. Coronary Flow Reserve is routinely measured in&#xD;
      patients with Acute Coronary Syndrome, without an increased risk of adverse events for&#xD;
      patients neither adjunctive costs for the National Health System.&#xD;
&#xD;
      Furthermore, Plasma concentrations of Ticagrelor and its main metabolite (AR-C124910XX) will&#xD;
      be measured in venous blood collected at the end of the procedure. In patients requiring a&#xD;
      second Percutaneous Coronary Intervention, for example for multivessel disease, all these&#xD;
      measures will be repeated in the same manner.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of coronary flow reserve</measure>
    <time_frame>2 hours after the loading dose of drugs.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Acute Coronary Syndrome:</condition>
  <condition>Non ST Elevation Myocardial Infarction</condition>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Assessment of Coronary Flow Reserve</intervention_name>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_label>ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_label>ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor loading</intervention_name>
    <arm_group_label>ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel loading</intervention_name>
    <arm_group_label>clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with acute coronary syndromes undergoing Percutaneous Coronary Intervention&#xD;
             with stent implantation;&#xD;
&#xD;
          -  Patients ≥ 18 and ≤ 75 years old.&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with stable angina;&#xD;
&#xD;
          -  prior myocardial infarction;&#xD;
&#xD;
          -  prior revascularization (Percutaneous Coronary Intervention or coronary artery bypass&#xD;
             grafting);&#xD;
&#xD;
          -  Clopidogrel and/or Ticagrelor contraindications (history of intracranial hemorrhage,&#xD;
             active pathological bleeding, severe hepatic impairment);&#xD;
&#xD;
          -  major periprocedural complications;&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 30 ml/min or requiring haemodialysis;&#xD;
&#xD;
          -  Non-sinus rhythm;&#xD;
&#xD;
          -  severe chronic obstructive pulmonary disease;&#xD;
&#xD;
          -  requirement for oral anticoagulant;&#xD;
&#xD;
          -  risk of bleeding or bradycardic events;&#xD;
&#xD;
          -  Ejection fraction &lt; 45%;&#xD;
&#xD;
          -  Cardiogenic shock;&#xD;
&#xD;
          -  Severe left ventricular hypertrophy;&#xD;
&#xD;
          -  severe valvular disease;&#xD;
&#xD;
          -  indication to coronary artery bypass grafting;&#xD;
&#xD;
          -  diffuse coronary atherosclerosis;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>massimo mancone, PhD</last_name>
    <phone>00390649979044</phone>
    <email>massimomancone@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massimo Mancone</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <phone>00390649970468</phone>
    </contact>
    <investigator>
      <last_name>massimo mancone, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Policlinico Umberto I</investigator_affiliation>
    <investigator_full_name>Massimo Mancone</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

